<p>Polaryx Therapeutics, Inc.（納斯達克代碼：PLYX - 獲取免費報告）在週二的交易中上漲了 4.9%。該公司的股價最高達到 6.49 美元，最後交易價為 6.47 美元。在交易中共成交 141,137 股，較平均交易量 2,268,150 股下降了 94%。該股票此前收盤價為 6.17 美元。</p>
<p>獲取 <strong>Polaryx Therapeutics</strong> 的提醒：</p>
<h2>分析師評級上調和下調</h2>
<p>另外，Maxim Group 在 2 月 27 日星期五發布的報告中開始覆蓋 Polaryx Therapeutics。他們對該股票設定了 “買入” 評級和 10.00 美元的目標價。一位投資分析師對該股票給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 10.00 美元。</p>
<p><strong>查看我們對 PLYX 的最新股票分析</strong></p>
<h2>Polaryx Therapeutics 股票上漲 4.9%</h2>
<h2>Polaryx Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>我們是一家臨牀階段的生物技術公司，致力於發現、開發和商業化新型的疾病修飾療法，針對罕見的兒童溶酶體儲存疾病（“LSDs”）。我們的治療理念集中在提供安全、有效且以患者為中心的治療，解決這些災難性疾病的潛在病理生理學及其顯著的未滿足需求。我們採用多模式的方法，整合小分子療法，包括聯合療法和基因療法，使我們能夠潛在地解決 LSDs 的遺傳和下游病理特徵。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Polaryx Therapeutics</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Polaryx Therapeutics 嗎？</h2>
<p>在考慮 Polaryx Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師，以及他們每天向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Polaryx Therapeutics 並不在名單上。</p>
<p>雖然 Polaryx Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PLYX

<p>Polaryx Therapeutics（納斯達克代碼：PLYX）股價上漲 4.9%，至 6.47 美元，儘管交易量大幅下降。Maxim Group 對其進行了覆蓋，給予 “買入” 評級，目標價為 10.00 美元。目前，該股票在分析師中持有平均 “買入” 評級，目標價為 10.00 美元。該公司專注於開發針對罕見兒童溶酶體貯積病的治療方案</p>

<p>Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) traded up 4.9% during trading on Tuesday . The company traded as high as $6.49 and last traded at $6.47. 141,137 shares were traded during trading, a decline of 94% from the average session volume of 2,268,150 shares. The stock had previously closed at $6.17.</p>
<div class="lb-trans"><p>Polaryx Therapeutics, Inc.（納斯達克代碼：PLYX - 獲取免費報告）在週二的交易中上漲了 4.9%。該公司的股價最高達到 6.49 美元，最後交易價為 6.47 美元。在交易中共成交 141,137 股，較平均交易量 2,268,150 股下降了 94%。該股票此前收盤價為 6.17 美元。</p>
</div><p>Get <strong>Polaryx Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Polaryx Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>Separately, Maxim Group started coverage on Polaryx Therapeutics in a report on Friday, February 27th. They set a &#34;buy&#34; rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $10.00.</p>
<div class="lb-trans"><p>另外，Maxim Group 在 2 月 27 日星期五發布的報告中開始覆蓋 Polaryx Therapeutics。他們對該股票設定了 “買入” 評級和 10.00 美元的目標價。一位投資分析師對該股票給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 10.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PLYX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 PLYX 的最新股票分析</strong></p>
</div><h2>Polaryx Therapeutics Stock Up 4.9%</h2>
<div class="lb-trans"><h2>Polaryx Therapeutics 股票上漲 4.9%</h2>
</div><h2>Polaryx Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Polaryx Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.</p>
<div class="lb-trans"><p>我們是一家臨牀階段的生物技術公司，致力於發現、開發和商業化新型的疾病修飾療法，針對罕見的兒童溶酶體儲存疾病（“LSDs”）。我們的治療理念集中在提供安全、有效且以患者為中心的治療，解決這些災難性疾病的潛在病理生理學及其顯著的未滿足需求。我們採用多模式的方法，整合小分子療法，包括聯合療法和基因療法，使我們能夠潛在地解決 LSDs 的遺傳和下游病理特徵。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Polaryx Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Polaryx Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Polaryx Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Polaryx Therapeutics 嗎？</h2>
</div><p>Before you consider Polaryx Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Polaryx Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Polaryx Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師，以及他們每天向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Polaryx Therapeutics 並不在名單上。</p>
</div><p>While Polaryx Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Polaryx Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Polaryx Therapeutics（NASDAQ:PLYX）股價上漲 4.9% - 現在是買入的好時機嗎？